| ViiV Healthcare Starts Phase III Clinical Programme of Celsentri/Selzentry ... - MarketWatch (press release) |
|
|
MarketWatch (press release) SELZENTRY should not be used in patients with severe renal impairment or end-stage renal disease (ESRD) (CrCl <30 mL/min) who are taking potent CYP3A inhibitors or inducers. Hepatotoxicity accompanied by severe rash or systemic allergic reaction |